Pharma

Your Unread Messages

See All

Tracy Hampton, PhD

FDA Update

Anti-CD20 Antibody Granted Accelerated Approval for CLL

Roberta Buell, MBA
CMS Revises Consignment Closet Provisions

Dorothy J. Schirf, MD

Technology Advances

Over-the-Counter Nanotech Test for Prostate Cancer Anticipated

Sara Hartley

Cancer Science

Using Embryonic Stem Cells to Test Breast Cancer Genes

See All Messages (38 new messages)

Your Article Summary

See Latest Articles

Repligen Reports Second Quarter Fiscal Year 2010 Financial Results
Repligen, 11/06/09

Repligen Corporation reported results for the second quarter of fiscal year 2010, ended September 30, 2009. Total revenue for the quarter was $5,421,000 compared to total revenue of $5,090,000 for the second quarter of fiscal year 2009 ended September 30, 2008. Total revenue for the second quarter of fiscal year 2010 was comprised of Protein A product revenue of $2,742,000 and royalty and research revenue of $2,679,000, consisting primarily of royalty payments from Bristol–Myers Squibb on the U.S. sales of Orencia.

Today in Financial Reports...keeping you current

Receive free subspecialty "5-minute updates" via email

Nabi Biopharmaceuticals Completes Sale of PentaStaph to GlaxoSmithKline PLC
Nabi Biopharmaceuticals, 11/05/09

CPSI Profits Down, Revenue Up
HealthDataManagement, 11/02/09

Ultrasound, nuc med on the upswing
Canadian Healthcare Technology, 10/16/09

See All of Financial Reports